logo

Relmada Therapeutics, Inc. (RLMD)



Trade RLMD now with
  Date
  Headline
12/3/2019 11:09:31 PM Relmada Therapeutics Announces Pricing Of Public Offering Of 3.33 Mln Shares At $30/Shr
12/3/2019 4:15:54 PM Relmada Therapeutics Announces Proposed Public Offering Of Common Stock
10/15/2019 8:05:07 AM Relmada Therapeutics Announces Top-Line Results From REL-1017 Phase 2 Study In Individuals With Resistant Depression
10/10/2019 8:35:23 AM Relmada Therapeutics Announces Commencement Of Trading On NASDAQ
9/27/2019 1:06:01 PM Relmada Therapeutics Announces 1-for-4 Reverse Stock Split
6/28/2017 8:07:28 AM Relmada Therapeutics Appoints Maurizio Fava As Chair Of Dextromethadone Scientific Advisory Board
6/15/2017 8:35:58 AM Relmada Therapeutics Names Charles Casamento Chairman Of Board
4/13/2017 8:07:28 AM Relmada Announces FDA Fast Track Designation For D-Methadone For Adjunctive Treatment Of Major Depressive Disorder
10/19/2016 8:32:55 AM Relmada Announces Issuance Of Key U.S. Patent Covering D-Methadone, An NMDA Receptor Antagonist
9/14/2016 8:35:37 AM Relmada Therapeutics Files Amended Complaint Against Laidlaw And Principals, Matthew Eitner And James Ahern
6/7/2016 8:33:05 AM Relmada Therapeutics' D-Methadone Receives Orphan Drug Designation For Management Of Postherpetic Neuralgia
12/23/2015 8:34:54 AM U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company And Principals Matthew Eitner & James Ahern